Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced Lung Adenocarcinoma and Review of Literature
Background and objective Afatinib is an irreversible ErbB-family blocker with a clinical activity in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. The aim of this study is to assess the safety of afatinib in patients with advanced lung adenocarcinoma. Methods Pat...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2014-04-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.09 |
id |
doaj-8225d537e6df4245818dc089f90af8bf |
---|---|
record_format |
Article |
spelling |
doaj-8225d537e6df4245818dc089f90af8bf2020-11-25T02:40:41ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34192014-04-0117434234610.3779/j.issn.1009-3419.2014.04.09Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of LiteratureHong TAO0Lili GUO1Junfang TANG2Yunzhong ZHU3Liyan XU4Qiyi MENG5Wei WU6Mingzhi LI7Weihua WU8Li TONG9Hongbo WU10Liang SHI11Zhe LIU12Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaBackground and objective Afatinib is an irreversible ErbB-family blocker with a clinical activity in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. The aim of this study is to assess the safety of afatinib in patients with advanced lung adenocarcinoma. Methods Patients with lung adenocarcinoma (stage IIIb or IV) with EGFR mutations were first-line treated with an oral administration of afatinib (40 mg/d) until disease progression. Adverse events, effects, and survival condition were observed. Results The most common adverse events were diarrhea (n=5, 100%), skin rash (n=4, 80%), and mucositis/stomatitis (n=4, 80%). Moderate toxicities not exceeding grade 3 were observed. Relatively, the most serious adverse reaction was mucositis/stomatitis. Mild diarrhea occurred in all patients. Three patients experienced temporary drug withdrawal and dose reduction because of adverse reaction. Among the four patients who were evaluated, partial response was observed in two patients (50%), one with stable disease (25%) and one with progressive disease (25%). Median progression-free survival was 9.7 months, whereas median overall survival was 18.4 months. Conclusion Afatinib was approved as first-line treatment for patients with advanced lung adenocarcinoma. The most common adverse events were diarrhea and skin rash. However, mucositis/stomatitis related to afatinib should also be considered. Considering the small number of cases, the conclusion requires more trials for confirmation.http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.09AfatinibEpidermal growth factor receptorTyrosine kinase inhibitorLung neoplasmsAdverse event |
collection |
DOAJ |
language |
zho |
format |
Article |
sources |
DOAJ |
author |
Hong TAO Lili GUO Junfang TANG Yunzhong ZHU Liyan XU Qiyi MENG Wei WU Mingzhi LI Weihua WU Li TONG Hongbo WU Liang SHI Zhe LIU |
spellingShingle |
Hong TAO Lili GUO Junfang TANG Yunzhong ZHU Liyan XU Qiyi MENG Wei WU Mingzhi LI Weihua WU Li TONG Hongbo WU Liang SHI Zhe LIU Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced Lung Adenocarcinoma and Review of Literature Chinese Journal of Lung Cancer Afatinib Epidermal growth factor receptor Tyrosine kinase inhibitor Lung neoplasms Adverse event |
author_facet |
Hong TAO Lili GUO Junfang TANG Yunzhong ZHU Liyan XU Qiyi MENG Wei WU Mingzhi LI Weihua WU Li TONG Hongbo WU Liang SHI Zhe LIU |
author_sort |
Hong TAO |
title |
Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of Literature |
title_short |
Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of Literature |
title_full |
Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of Literature |
title_fullStr |
Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of Literature |
title_full_unstemmed |
Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of Literature |
title_sort |
adverse events of afatinib as first-line treatment for five cases of advanced
lung adenocarcinoma and review of literature |
publisher |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
series |
Chinese Journal of Lung Cancer |
issn |
1009-3419 |
publishDate |
2014-04-01 |
description |
Background and objective Afatinib is an irreversible ErbB-family blocker with a clinical activity in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. The aim of this study is to assess the safety of afatinib in patients with advanced lung adenocarcinoma. Methods Patients with lung adenocarcinoma (stage IIIb or IV) with EGFR mutations were first-line treated with an oral administration of afatinib (40 mg/d) until disease progression. Adverse events, effects, and survival condition were observed. Results The most common adverse events were diarrhea (n=5, 100%), skin rash (n=4, 80%), and mucositis/stomatitis (n=4, 80%). Moderate toxicities not exceeding grade 3 were observed. Relatively, the most serious adverse reaction was mucositis/stomatitis. Mild diarrhea occurred in all patients. Three patients experienced temporary drug withdrawal and dose reduction because of adverse reaction. Among the four patients who were evaluated, partial response was observed in two patients (50%), one with stable disease (25%) and one with progressive disease (25%). Median progression-free survival was 9.7 months, whereas median overall survival was 18.4 months. Conclusion Afatinib was approved as first-line treatment for patients with advanced lung adenocarcinoma. The most common adverse events were diarrhea and skin rash. However, mucositis/stomatitis related to afatinib should also be considered. Considering the small number of cases, the conclusion requires more trials for confirmation. |
topic |
Afatinib Epidermal growth factor receptor Tyrosine kinase inhibitor Lung neoplasms Adverse event |
url |
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.09 |
work_keys_str_mv |
AT hongtao adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT liliguo adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT junfangtang adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT yunzhongzhu adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT liyanxu adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT qiyimeng adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT weiwu adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT mingzhili adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT weihuawu adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT litong adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT hongbowu adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT liangshi adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature AT zheliu adverseeventsofafatinibasfirstlinetreatmentforfivecasesofadvancedlungadenocarcinomaandreviewofliterature |
_version_ |
1724780315646361600 |